MA64013B1 - Formes solides et formulations de (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a!pyrazin-1-yl)-n-(pyridin-2-yl)benzamide - Google Patents

Formes solides et formulations de (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a!pyrazin-1-yl)-n-(pyridin-2-yl)benzamide

Info

Publication number
MA64013B1
MA64013B1 MA64013A MA64013A MA64013B1 MA 64013 B1 MA64013 B1 MA 64013B1 MA 64013 A MA64013 A MA 64013A MA 64013 A MA64013 A MA 64013A MA 64013 B1 MA64013 B1 MA 64013B1
Authority
MA
Morocco
Prior art keywords
solid forms
ynoyl
pyrazin
imidazo
pyrrolidin
Prior art date
Application number
MA64013A
Other languages
English (en)
Inventor
Jerry Evarts
Tjeerd Barf
Fritz Blatter
Tim INGALLINERA
Edwin Aret
Cecile Krejsa
Original Assignee
Acerta Pharma B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56363881&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA64013(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Acerta Pharma B.V. filed Critical Acerta Pharma B.V.
Publication of MA64013B1 publication Critical patent/MA64013B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)

Abstract

Dans certains modes de réalisation, l'invention concerne des formes solides cristallines, y compris des polymorphes, des hydrates et des formes de sel, de (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide. Dans certains modes de réalisation, l'invention concerne également des compositions pharmaceutiques contenant les formes solides cristallines, et des méthodes de traitement d'affections ou de troubles par l'administration à un sujet d'une composition pharmaceutique qui comprend les formes, y compris des compositions pharmaceutiques et des méthodes pour surmonter les effets des agents réducteurs d'acide.
MA64013A 2015-07-02 2016-07-01 Formes solides et formulations de (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a!pyrazin-1-yl)-n-(pyridin-2-yl)benzamide MA64013B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562188468P 2015-07-02 2015-07-02
US201562271708P 2015-12-28 2015-12-28
EP23157244.7A EP4209493B1 (fr) 2015-07-02 2016-07-01 Formes solides et formulations de (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a!pyrazin-1-yl)-n-(pyridin-2-yl)benzamide

Publications (1)

Publication Number Publication Date
MA64013B1 true MA64013B1 (fr) 2026-01-30

Family

ID=56363881

Family Applications (2)

Application Number Title Priority Date Filing Date
MA50817A MA50817B1 (fr) 2015-07-02 2016-07-01 Formes et formulations solides de (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide
MA64013A MA64013B1 (fr) 2015-07-02 2016-07-01 Formes solides et formulations de (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a!pyrazin-1-yl)-n-(pyridin-2-yl)benzamide

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA50817A MA50817B1 (fr) 2015-07-02 2016-07-01 Formes et formulations solides de (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide

Country Status (28)

Country Link
US (7) US9796721B2 (fr)
EP (4) EP3613745B1 (fr)
JP (3) JP6829215B2 (fr)
KR (2) KR20240115937A (fr)
CN (2) CN108349978B (fr)
AU (3) AU2016286548B2 (fr)
CL (1) CL2017003445A1 (fr)
CY (3) CY1124519T1 (fr)
DK (4) DK3317281T3 (fr)
ES (4) ES3059433T3 (fr)
FI (2) FI3954690T3 (fr)
HR (4) HRP20260050T1 (fr)
HU (3) HUE062258T2 (fr)
IL (3) IL293821A (fr)
LT (4) LT4209493T (fr)
MA (2) MA50817B1 (fr)
MD (1) MD3317281T2 (fr)
MX (2) MX2020014163A (fr)
MY (1) MY193514A (fr)
PL (4) PL4209493T3 (fr)
PT (4) PT3613745T (fr)
RS (4) RS60411B1 (fr)
RU (1) RU2018103913A (fr)
SG (1) SG10201913796UA (fr)
SI (4) SI3954690T1 (fr)
SM (4) SMT202600010T1 (fr)
WO (1) WO2017002095A1 (fr)
ZA (2) ZA201800329B (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SMT202100674T1 (it) * 2014-08-11 2022-01-10 Acerta Pharma Bv Combinazioni terapeutiche di un inibitore di btk e un inibitore di bcl-2
IL293821A (en) 2015-07-02 2022-08-01 Acerta Pharma Bv Solid forms and formulations of (S)-4-(8-amino-3-(1-(but-2-aminoyl)pyrrolidine-2-yl)imidazo[5,1-yl]pyrazin-1-yl)-en- (pyridine-2-yl)benzamide
HRP20240136T1 (hr) 2016-06-29 2024-04-12 Tesaro, Inc. Metode liječenja raka jajnika
WO2018064797A1 (fr) 2016-10-05 2018-04-12 杭州领业医药科技有限公司 Forme cristalline d'acp-196, procédé de préparation et composition pharmaceutique associés
WO2018115965A1 (fr) * 2016-12-23 2018-06-28 Acerta Pharma Bv Formes solides de composés d'imidazopyrazine
US10899770B2 (en) 2017-02-20 2021-01-26 Hangzhou Solipharma Co., Ltd. Crystal form of ACP-196 salt and preparation method, pharmaceutical composition, and use thereof
EP3606523A1 (fr) * 2017-03-27 2020-02-12 Tesaro, Inc. Formulations de niraparib
AU2018246214B2 (en) 2017-03-27 2021-07-08 Merck Sharp & Dohme Llc Niraparib compositions
WO2018229613A1 (fr) * 2017-06-13 2018-12-20 Dr. Reddy's Laboratories Limited Formes solides d'acalabrutinib et procédé de préparation correspondant
WO2019041026A1 (fr) * 2017-08-29 2019-03-07 Apotex Inc. Nouvelles formes cristallines d'acalabrutinib
CN111278433A (zh) 2017-09-26 2020-06-12 特沙诺有限公司 尼拉帕尼制剂
WO2019105359A1 (fr) * 2017-11-30 2019-06-06 苏州科睿思制药有限公司 Forme cristalline de l'acalabrutinib, son procédé de préparation et son application
KR20200106511A (ko) * 2018-01-05 2020-09-14 크리스탈 파마슈티컬 (쑤저우) 씨오., 엘티디. 아칼라브루티닙의 신규 결정형 및 그 제조방법 및 용도
WO2019159097A1 (fr) * 2018-02-14 2019-08-22 Sun Pharmaceutical Industries Limited Nouvelles formes polymorphes cristallines d'acalabrutinib
WO2019205812A1 (fr) * 2018-04-26 2019-10-31 苏州科睿思制药有限公司 Nouvelle forme cristalline de l'acalabrutinib, son procédé de préparation et son utilisation
EP3587421A1 (fr) 2018-06-29 2020-01-01 Sandoz AG Formes cristallines de (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo [1,5-alpha]pyrazin-1-yl-n-(pyridin-2-yl)benzamide
KR20250119664A (ko) 2018-08-29 2025-08-07 아세르타 파마. 비.브이. 4-｛8-아미노-3-[(2S)-1-(부트-2-이노일)-피롤리딘-2-일]이미다조[1,5-a]-피라진-1-일｝N-(피리딘-2-일)-벤즈아미드의제조 공정
WO2020053795A2 (fr) 2018-09-13 2020-03-19 Fresenius Kabi Oncology Ltd. Procédé de préparation d'acalabrutinib et de ses intermédiaires
WO2020065667A1 (fr) 2018-09-25 2020-04-02 Cipla Limited Nouveaux polymorphes d'acalabrutinib, un inhibiteur de la tyrosine kinase de bruton
EP3947386A1 (fr) 2019-03-27 2022-02-09 Assia Chemical Industries Ltd Formes à l'état solide d'acalabrutinib
WO2020225831A1 (fr) * 2019-05-09 2020-11-12 Msn Laboratories Private Limited, R&D Center Procédé amélioré pour la préparation de 4-{8-amino-3-[(2s)-1-(but-2-ynoyl)pyrrolidin-2-yl] imidazo[1,5-a]pyrazin-1-yl)}-n-(pyridine-2-yl)benzamide
WO2021111465A1 (fr) 2019-12-02 2021-06-10 Natco Pharma Limited Nouveau procédé de préparation d'acalabrutinib et de ses intermédiaires
WO2021135346A1 (fr) * 2019-12-31 2021-07-08 苏州科睿思制药有限公司 Nouvelle forme cristalline de l'acalabrutinib, son procédé de préparation et son utilisation
CA3168764A1 (fr) 2020-02-26 2021-09-02 Alexander J. Stirk Procedes de preparation de formes cristallines a plusieurs composants d'ingredients pharmaceutiques actifs a l'aide de vapeur de solvant
WO2021239893A1 (fr) 2020-05-29 2021-12-02 Bend Research, Inc. Dispersion solide amorphe d'acalabrutinib
CR20230018A (es) * 2020-06-19 2023-04-11 Acerta Pharma Bv Formas farmacéuticas de maleato de acalabrutinib
CN112028896A (zh) * 2020-10-14 2020-12-04 奥锐特药业(天津)有限公司 阿卡替尼的新晶型及其制备方法
US20240315978A1 (en) * 2021-01-13 2024-09-26 Natco Pharma Limited Pharmaceutical compositions comprising acalabrutinib
WO2023014817A1 (fr) 2021-08-03 2023-02-09 Syros Pharmaceuticals, Inc. Compositions et méthodes pour traiter des lymphomes avec un inhibiteur de cdk7 en combinaison avec un inhibiteur de btk
WO2023205279A1 (fr) * 2022-04-19 2023-10-26 The Johns Hopkins University Spectroscopie raman améliorée avec addition de composés aromatiques
WO2024164066A1 (fr) * 2023-02-09 2024-08-15 Apotex Inc Formes cristallines de maléate d'acalabrutinib
WO2025125383A1 (fr) 2023-12-11 2025-06-19 Synthon B.V. Formes cristallines d'hydrogénomaléate d'acalabrutinib
WO2026117542A1 (fr) 2024-11-26 2026-06-04 Arvinas Operations, Inc. Thérapie combinée pour la dégradation ciblée de bcl6

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001081031A (ja) 1999-08-30 2001-03-27 Schering Ag 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
HK1053831A1 (zh) 1999-09-17 2003-11-07 Basf Aktiengesellschaft 作为治疗药物的激酶抑制剂
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
US6998391B2 (en) 2002-02-07 2006-02-14 Supergen.Inc. Method for treating diseases associated with abnormal kinase activity
ES2372694T3 (es) 2003-10-15 2012-01-25 OSI Pharmaceuticals, LLC Inhibidores de tirosina cinasa de imidazo[1,5-a]pirazina.
MXPA06011423A (es) 2004-04-02 2007-01-23 Osi Pharm Inc Inhibidores de proteina cinasa heterobiciclica sustituida en el anillo 6,6-biciclico.
ITMI20051231A1 (it) 2005-06-29 2006-12-30 Pharmaproducts Uk Ltd Formulazioni farmaceutiche contenenti colostro e calcio folinato per il trattamento delle affezioni del cavo orale
SI1931346T1 (sl) 2005-09-09 2012-10-30 Angelini Labopharm Llc Trazodonski sestavek za dajanje enkrat dnevno
CA2630271C (fr) 2005-11-17 2014-04-08 Osi Pharmaceuticals, Inc. Inhibiteurs mtor bicycliques condenses
PE20070855A1 (es) 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
AR057960A1 (es) 2005-12-02 2007-12-26 Osi Pharm Inc Inhibidores de proteina quinasa biciclicos
WO2007106503A2 (fr) 2006-03-13 2007-09-20 Osi Pharmaceuticals, Inc. Traitement combiné avec un inhibiteur de kinase egfr et un agent sensibilisant les cellules tumorales aux effets des inhibiteurs de kinase egfr
EP2529621B1 (fr) 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibiteurs de la tyrosine kinase de bruton
EP2139487B1 (fr) 2007-03-28 2015-11-11 Pharmacyclics LLC Inhibiteurs de la tyrosine kinase de bruton
US8809273B2 (en) 2007-03-28 2014-08-19 Pharmacyclics, Inc. Inhibitors of Bruton's tyrosine kinase
US8088824B2 (en) * 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester
AU2008335469A1 (en) 2007-12-13 2009-06-18 Novartis Ag Combinations of therapeutic agents for treating cancer
US9095592B2 (en) 2008-11-07 2015-08-04 The Research Foundation For The State University Of New York Bruton's tyrosine kinase as anti-cancer drug target
US8299077B2 (en) 2009-03-02 2012-10-30 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
US8765754B2 (en) 2009-04-29 2014-07-01 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds
US8658794B2 (en) 2010-02-08 2014-02-25 Merck Sharp & Dohme B.V. 8-methyl-1-phenyl-imidazol[1,5-a]pyrazine compounds as Lck inhibitors and uses thereof
CN102190594A (zh) * 2010-03-17 2011-09-21 上海医药工业研究院 阿戈美拉汀氯化氢水合物及其制备方法
UY33288A (es) 2010-03-25 2011-10-31 Glaxosmithkline Llc Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico
US8940725B2 (en) 2010-05-31 2015-01-27 Ono Pharmaceutical Co., Ltd. Purinone derivative
MX380504B (es) 2010-06-03 2025-03-12 Pharmacyclics Llc El uso de inhibidores de la tirosina quinasa de bruton (btk).
US20120053189A1 (en) 2010-06-28 2012-03-01 Pharmacyclics, Inc. Btk inhibitors for the treatment of immune mediated conditions
DK2710007T3 (da) 2011-05-17 2020-01-27 Principia Biopharma Inc Kinasehæmmere
WO2013003629A2 (fr) 2011-06-28 2013-01-03 Pharmacyclics, Inc. Procédés et compositions visant à inhiber la résorption osseuse
KR20140048968A (ko) 2011-07-13 2014-04-24 파마시클릭스, 인코포레이티드 브루톤형 티로신 키나제의 억제제
EP2548877A1 (fr) 2011-07-19 2013-01-23 MSD Oss B.V. Dérivés de 4-(pyridine condensée à 5 chaînons)benzamide comme inhibiteurs de BTK
WO2013010869A1 (fr) 2011-07-19 2013-01-24 Msd Oss B.V. 4-imidazopyridazin-1-yl-benzamides et 4-imidazotriazin-1-yl-benzamides inhibiteurs de btk
CN103889987B (zh) * 2011-07-19 2016-09-14 默沙东有限责任公司 作为btk抑制剂的选择的咪唑并吡嗪类
US20140303191A1 (en) 2011-10-19 2014-10-09 Pharmacyclics, Inc. Use of inhibitors of bruton's tyrosine kinase (btk)
US20140212425A1 (en) 2011-12-05 2014-07-31 Immunomedics, Inc. Therapeutic use of anti-cd22 antibodies for inducing trogocytosis
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
NZ703124A (en) * 2012-05-23 2016-07-29 Nerviano Medical Sciences Srl Process for the preparation of n-[5-(3,5-difluoro-benzyl)-1h-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide
US9481682B2 (en) 2013-01-23 2016-11-01 Merck Sharp & Dohme Corp. Substituted benzamides and substituted pyridinecarboxamides as Btk inhibitors
AU2014244518A1 (en) 2013-03-14 2015-09-17 Pharmacyclics Llc Combinations of Bruton's tyrosine kinase inhibitors and CYP3A4 inhibitors
WO2014143807A2 (fr) 2013-03-15 2014-09-18 Stromatt Scott Anticorps anti-cd37 et polythérapie par antagoniste de la voie bcr pour le traitement de malignités b et de troubles des lymphocytes b
US20160287592A1 (en) 2013-04-08 2016-10-06 Pharmacyclics Llc Ibrutinib combination therapy
AP2015008750A0 (en) 2013-04-08 2015-09-30 Bayer Pharma AG Use of substituted 2,3-dihydroimidazo[1,2-c] quinazolines for treating lymphomas
WO2015018522A1 (fr) 2013-08-06 2015-02-12 Oncoethix Sa Inhibiteur de bromodomaine bet présentant une synergie avec plusieurs agents anti-cancéreux dans des modèles cliniques de lymphome diffus de cellule b de grande taille (dlbcl)
WO2015057992A1 (fr) * 2013-10-16 2015-04-23 Izumi Raquel Inhibiteurs btk pour la mobilisation hématopoïétique
EP3076974A1 (fr) 2013-12-05 2016-10-12 Acerta Pharma B.V. Association thérapeutique d'un inhibiteur de pi3k et d'un inhibiteur de btk
JP6219523B2 (ja) 2013-12-13 2017-10-25 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ブルトンチロシンキナーゼの阻害剤
WO2015110923A2 (fr) 2014-01-21 2015-07-30 Acerta Pharma B.V. Méthodes de traitement de la leucémie lymphoïde chronique et du lymphome à petits lymphocytes en utilisant un inhibiteur de btk
FR3021783B1 (fr) 2014-06-02 2016-05-13 Morpho Procede de validation de l'authenticite d'un element du corps humain
IL293821A (en) 2015-07-02 2022-08-01 Acerta Pharma Bv Solid forms and formulations of (S)-4-(8-amino-3-(1-(but-2-aminoyl)pyrrolidine-2-yl)imidazo[5,1-yl]pyrazin-1-yl)-en- (pyridine-2-yl)benzamide

Also Published As

Publication number Publication date
PT3613745T (pt) 2021-10-14
SMT202300165T1 (it) 2023-07-20
DK3613745T3 (da) 2021-10-18
CY1124519T1 (el) 2022-03-24
PL4209493T3 (pl) 2026-05-25
RU2018103913A3 (fr) 2019-12-31
RS60411B1 (sr) 2020-07-31
CY1126103T1 (el) 2023-11-15
JP2022120156A (ja) 2022-08-17
DK3317281T3 (da) 2020-06-15
LT3613745T (lt) 2021-10-11
KR20180048593A (ko) 2018-05-10
LT3954690T (lt) 2023-05-25
AU2020277123A1 (en) 2020-12-24
US20200255437A1 (en) 2020-08-13
EP3954690B1 (fr) 2023-04-05
KR20240115937A (ko) 2024-07-26
LT4209493T (lt) 2026-01-26
PT4209493T (pt) 2026-01-08
HRP20200934T1 (hr) 2020-09-18
SMT202600010T1 (it) 2026-03-09
SG10201913796UA (en) 2020-03-30
US10167291B2 (en) 2019-01-01
MA50817A (fr) 2021-04-21
AU2016286548B2 (en) 2020-12-10
LT3317281T (lt) 2020-07-27
SMT202100597T1 (it) 2021-11-12
CL2017003445A1 (es) 2018-05-11
SMT202000304T1 (it) 2020-07-08
PT3317281T (pt) 2020-06-18
EP3954690A1 (fr) 2022-02-16
AU2016286548A1 (en) 2018-02-01
MX2020014163A (es) 2022-09-29
US20220348582A1 (en) 2022-11-03
ES2895802T3 (es) 2022-02-22
US11059829B2 (en) 2021-07-13
ZA202000300B (en) 2022-03-30
JP6829215B2 (ja) 2021-02-10
PL3317281T3 (pl) 2020-11-02
MD3317281T2 (ro) 2020-07-31
US20240199622A1 (en) 2024-06-20
US10640509B2 (en) 2020-05-05
PL3613745T3 (pl) 2022-01-31
US20190337949A1 (en) 2019-11-07
SI3954690T1 (sl) 2023-07-31
FI3954690T3 (fi) 2023-05-31
IL274066A (en) 2020-06-30
ES2946489T3 (es) 2023-07-19
EP4209493A1 (fr) 2023-07-12
CN108349978A (zh) 2018-07-31
EP3613745B1 (fr) 2021-09-01
RS67620B1 (sr) 2026-02-27
IL293821A (en) 2022-08-01
IL256633B (en) 2020-05-31
MX378495B (es) 2025-03-11
DK3954690T3 (da) 2023-06-06
AU2022291635A1 (en) 2023-02-02
JP7091494B2 (ja) 2022-06-27
DK4209493T3 (da) 2026-02-02
CN113480542A (zh) 2021-10-08
CY1124815T1 (el) 2022-11-25
ZA201800329B (en) 2022-04-28
JP2018522877A (ja) 2018-08-16
MA50817B1 (fr) 2021-10-29
US11820777B2 (en) 2023-11-21
US20180208596A1 (en) 2018-07-26
JP7834584B2 (ja) 2026-03-24
IL256633A (en) 2018-02-28
MX2018000179A (es) 2018-06-27
US20170029428A1 (en) 2017-02-02
SI3613745T1 (sl) 2021-12-31
CN113480542B (zh) 2025-07-25
EP3317281B1 (fr) 2020-04-22
HRP20230417T1 (hr) 2023-07-07
CA2991096A1 (fr) 2017-01-05
US20220177476A1 (en) 2022-06-09
JP2021073235A (ja) 2021-05-13
RS64195B1 (sr) 2023-06-30
EP3317281A1 (fr) 2018-05-09
AU2022291635B2 (en) 2024-06-27
MY193514A (en) 2022-10-17
HUE056008T2 (hu) 2022-01-28
PT3954690T (pt) 2023-06-06
IL274066B (en) 2022-07-01
US9796721B2 (en) 2017-10-24
HUE062258T2 (hu) 2023-10-28
WO2017002095A1 (fr) 2017-01-05
ES2797987T3 (es) 2020-12-04
EP4209493B1 (fr) 2025-11-12
EP3613745A1 (fr) 2020-02-26
AU2020277123B2 (en) 2022-09-29
HRP20260050T1 (hr) 2026-02-27
CN108349978B (zh) 2021-07-23
SI3317281T1 (sl) 2020-08-31
KR102688052B1 (ko) 2024-07-25
RU2018103913A (ru) 2019-08-02
SI4209493T1 (sl) 2026-05-29
HK1250511A1 (en) 2018-12-21
HUE049989T2 (hu) 2020-11-30
HRP20211511T1 (hr) 2021-12-24
RS62455B1 (sr) 2021-11-30
PL3954690T3 (pl) 2023-08-14
FI4209493T3 (fi) 2026-01-19
ES3059433T3 (en) 2026-03-20

Similar Documents

Publication Publication Date Title
MY193514A (en) Solid forms and formulations of (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1, 5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide
PH12015501964A1 (en) Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
NZ708593A (en) Novel pyrazole derivative
MX2021013110A (es) Compuestos heterociclicos como inhibidores de la cinasa ret.
JOP20190094A1 (ar) مركبات 1، 2، 4-تريازولون تحمل ثلاثة بدائل عند المواقع 2، 4، 5 مفيدة كمثبطات لديهيدروجيناز ثنائي هيدرو أوروتات (dhodh)
PH12015501661A1 (en) Pyridone amides as modulators of sodium channels
NZ732154A (en) Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
NZ710111A (en) Quinoline and quinoxaline amides as modulators of sodium channels
PH12016500105A1 (en) Sulfonamides as modulators of sodium channels
PH12015502615B1 (en) Chemical compounds
MX2014000779A (es) Derivados de carboxamida y urea que contienen pirazol heteroaromatico sustituido como ligandos del receptor de vanilloide.
MX2017004950A (es) Composiciones y metodos para tratar el insomnio.
PH12013501758A1 (en) Pyrazolo [1,5-a] pyridines as trk inhibitors
MX336051B (es) Diarilacetileno hidracido que contiene inhibidores de tirosina quinasa.
WO2012135697A3 (fr) Nouveaux inhibiteurs de la rho-kinase et leurs procédés d'utilisation
MX2014000964A (es) Derivados aza heterociclicos sustituidos.
EA201591541A1 (ru) Ингибиторы бета-секретазы 1 (bace 1)
SG10201907289VA (en) Monomethylfumarate prodrug compositions
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
EA032654B9 (ru) [1,2,4]ТРИАЗОЛО[4,3-b]ПИРИДАЗИНЫ ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ ПРОЛИФЕРАТИВНЫХ ЗАБОЛЕВАНИЙ
IN2014KN00849A (fr)
MX2014003584A (es) Derivados de metanosulfonamida sustituidos como ligandos de receptores vaniloides.
MX2017011652A (es) (indazol-4-il)hexahidropirrolopirrolones y metodos de uso.
IN2013MU01222A (fr)
TN2013000150A1 (en) Co-crystals and salts of ccr3-inhibitors